318 related articles for article (PubMed ID: 31875307)
21. Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study.
Wei KC; Chu PC; Wang HY; Huang CY; Chen PY; Tsai HC; Lu YJ; Lee PY; Tseng IC; Feng LY; Hsu PW; Yen TC; Liu HL
PLoS One; 2013; 8(3):e58995. PubMed ID: 23527068
[TBL] [Abstract][Full Text] [Related]
22. Induction Therapy of Retinoic Acid with a Temozolomide-Loaded Gold Nanoparticle-Associated Ultrasound Effect on Glioblastoma Cancer Stem-Like Colonies.
Fadera S; Chen PY; Liu HL; Lee IC
ACS Appl Mater Interfaces; 2021 Jul; 13(28):32845-32855. PubMed ID: 34235925
[TBL] [Abstract][Full Text] [Related]
23. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
[TBL] [Abstract][Full Text] [Related]
24. Molecular biological investigation of temozolomide and KC7F2 combination in U87MG glioma cell line.
Abbaszade Z; Bagca BG; Avci CB
Gene; 2021 Apr; 776():145445. PubMed ID: 33484758
[TBL] [Abstract][Full Text] [Related]
25. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
[TBL] [Abstract][Full Text] [Related]
26. Low Dose of Doxorubicin Potentiates the Effect of Temozolomide in Glioblastoma Cells.
Villodre ES; Kipper FC; Silva AO; Lenz G; Lopez PLDC
Mol Neurobiol; 2018 May; 55(5):4185-4194. PubMed ID: 28612256
[TBL] [Abstract][Full Text] [Related]
27. Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids.
Günther W; Pawlak E; Damasceno R; Arnold H; Terzis AJ
Br J Cancer; 2003 Feb; 88(3):463-9. PubMed ID: 12569392
[TBL] [Abstract][Full Text] [Related]
28. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
29. Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy?
Qu J; Zhang L; Chen Z; Mao G; Gao Z; Lai X; Zhu X; Zhu J
Drug Deliv; 2016 Nov; 23(9):3408-3416. PubMed ID: 27181462
[TBL] [Abstract][Full Text] [Related]
30. Gene Therapy for Drug-Resistant Glioblastoma via Lipid-Polymer Hybrid Nanoparticles Combined with Focused Ultrasound.
Yang Q; Zhou Y; Chen J; Huang N; Wang Z; Cheng Y
Int J Nanomedicine; 2021; 16():185-199. PubMed ID: 33447034
[TBL] [Abstract][Full Text] [Related]
31. Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy.
Zong Z; Hua L; Wang Z; Xu H; Ye C; Pan B; Zhao Z; Zhang L; Lu J; Mei LH; Rutong Y
Drug Deliv; 2019 Dec; 26(1):34-44. PubMed ID: 30744436
[TBL] [Abstract][Full Text] [Related]
32. Glioblastoma spheroid growth and chemotherapeutic responses in single and dual-stiffness hydrogels.
Bruns J; Egan T; Mercier P; Zustiak SP
Acta Biomater; 2023 Jun; 163():400-414. PubMed ID: 35659918
[TBL] [Abstract][Full Text] [Related]
33. Effects of Far-infrared Ray on Temozolomide-treated Glioma in Rats.
Chen JC; Hwang JH
In Vivo; 2019; 33(4):1203-1208. PubMed ID: 31280210
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
[TBL] [Abstract][Full Text] [Related]
35. Novel nanohydrogel of hyaluronic acid loaded with quercetin alone and in combination with temozolomide as new therapeutic tool, CD44 targeted based, of glioblastoma multiforme.
Barbarisi M; Iaffaioli RV; Armenia E; Schiavo L; De Sena G; Tafuto S; Barbarisi A; Quagliariello V
J Cell Physiol; 2018 Oct; 233(10):6550-6564. PubMed ID: 29030990
[TBL] [Abstract][Full Text] [Related]
36. Radiotherapy, Temozolomide, and Antiprogrammed Cell Death Protein 1 Treatments Modulate the Immune Microenvironment in Experimental High-Grade Glioma.
Riva M; Wouters R; Sterpin E; Giovannoni R; Boon L; Himmelreich U; Gsell W; Van Ranst M; Coosemans A
Neurosurgery; 2021 Jan; 88(2):E205-E215. PubMed ID: 33289503
[TBL] [Abstract][Full Text] [Related]
37. Studies examining the synergy between Dihydrotanshinone and Temozolomide against MGMT+ glioblastoma cells in vitro: Predicting interactions with the blood-brain barrier.
Kumar V; Radin D; Leonardi D
Biomed Pharmacother; 2019 Jan; 109():386-390. PubMed ID: 30399573
[TBL] [Abstract][Full Text] [Related]
38. An image guided small animal radiation therapy platform (SmART) to monitor glioblastoma progression and therapy response.
Yahyanejad S; van Hoof SJ; Theys J; Barbeau LM; Granton PV; Paesmans K; Verhaegen F; Vooijs M
Radiother Oncol; 2015 Sep; 116(3):467-72. PubMed ID: 26163089
[TBL] [Abstract][Full Text] [Related]
39. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
40. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
Liu T; Li A; Xu Y; Xin Y
Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
